ASL Financial LLC Makes New $704,000 Investment in Amgen Inc. $AMGN

ASL Financial LLC bought a new position in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,150 shares of the medical research company’s stock, valued at approximately $704,000.

A number of other hedge funds have also modified their holdings of the business. Brighton Jones LLC boosted its stake in Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares during the last quarter. Sivia Capital Partners LLC boosted its position in shares of Amgen by 10.6% during the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after acquiring an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of Amgen by 29.3% in the second quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock valued at $7,220,000 after purchasing an additional 5,853 shares during the period. Arrowstreet Capital Limited Partnership purchased a new stake in shares of Amgen in the second quarter valued at about $59,836,000. Finally, Groupe la Francaise acquired a new stake in Amgen during the second quarter worth about $222,000. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Amgen Stock Down 1.5%

NASDAQ:AMGN opened at $347.94 on Friday. The company has a quick ratio of 0.90, a current ratio of 1.14 and a debt-to-equity ratio of 5.78. The stock’s fifty day moving average is $363.59 and its two-hundred day moving average is $331.85. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29. The stock has a market capitalization of $187.56 billion, a price-to-earnings ratio of 24.45, a price-to-earnings-growth ratio of 3.50 and a beta of 0.47.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. The business had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company’s revenue was up 8.6% on a year-over-year basis. During the same period in the previous year, the firm posted $5.31 earnings per share. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Research analysts anticipate that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 5th. Shareholders of record on Friday, May 15th will be paid a dividend of $2.52 per share. The ex-dividend date is Friday, May 15th. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. Amgen’s dividend payout ratio is 70.84%.

Analyst Upgrades and Downgrades

Several research firms have weighed in on AMGN. Cantor Fitzgerald boosted their target price on shares of Amgen from $315.00 to $350.00 and gave the company a “neutral” rating in a report on Wednesday, February 4th. Guggenheim raised their price target on shares of Amgen from $305.00 to $347.00 and gave the stock a “neutral” rating in a report on Friday, February 6th. Truist Financial upped their price objective on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a report on Thursday, January 8th. Morgan Stanley raised their target price on Amgen from $304.00 to $309.00 and gave the stock an “equal weight” rating in a research note on Wednesday, February 4th. Finally, Barclays assumed coverage on Amgen in a research report on Friday, February 20th. They issued an “equal weight” rating and a $350.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.